3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
7
Peritoneal Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Appendiceal Neoplasms
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Pseudomyxoma Peritonei
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms
2
Anus Neoplasms
2
Uterine Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Sarcoma
1
Pleural Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Necrosis
1
Mediastinal Neoplasms
1
Male Urogenital Diseases
1
Gastrointestinal Neoplasms
1
Female Urogenital Diseases
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Specimen Handling
10
Paclitaxel
6
Platinum
5
Cyclophosphamide
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
4
durvalumab
4
cemiplimab
4
Radiotherapy, Intensity-Modulated
4
Radiotherapy
3
Pemetrexed
3
Oxaliplatin
3
Nivolumab
3
Fluorouracil
3
Cetuximab
3
Carboplatin
3
Biopsy
3
poly ICLC
2
fludarabine phosphate
2
cabozantinib
2
atezolizumab
2
Radiation
2
Ipilimumab
2
Interviews as Topic
2
Heavy Ion Radiotherapy
2
Gemcitabine
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma
×
Mitomycin
×
Clear all
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled